C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 235/54 (2006.01) A61K 31/16 (2006.01) A61K 31/33 (2006.01) A61P 9/00 (2006.01) A61P 29/00 (2006.01) C07C 317/22 (2006.01) C07C 317/46 (2006.01) C07C 323/62 (2006.01) C07D 209/12 (2006.01) C07D 211/22 (2006.01) C07D 213/30 (2006.01) C07D 213/64 (2006.01) C07D 213/65 (2006.01) C07D 213/81 (2006.01) C07D 261/04 (2006.01) C07D 277/56 (2006.01) C07D 307/12 (2006.01) C07D 319/20 (2006.01) C07D 333/32 (2006.01) C07D 333/80 (2006.01)
Patent
CA 2723302
The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA, receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.
La présente invention concerne des composés qui sont représentés par la formule (I) dans laquelle A, Y, Z, R3 à R6, R20 à R22 et R50 ont les significations données dans les revendications et qui constituent des composés pharmaceutiques actifs intéressants. En l'occurrence, ce sont des inhibiteurs du récepteur 2 du gène de différentiation endothéliale (Edg-2, EDG2) qui est activé par l'acide lysophosphatidique (LPA) et que l'on appelle également LPA1. Ces composés conviennent au traitement d'affections telles que l'athérosclérose, l'infarctus du myocarde et l'insuffisance cardiaque. L'invention concerne en outre des procédés destinés à l'élaboration des composés représentés par la formule (I), leur utilisation, et des compositions pharmaceutique les comprenant.
Chen L. Charlie
Czechtizky Werngard
Kadereit Dieter
Patek Marcel
Pernerstorfer Josef
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Sanofi-Aventis
LandOfFree
Acylamino-substituted fused cyclopentanecarboxylic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylamino-substituted fused cyclopentanecarboxylic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylamino-substituted fused cyclopentanecarboxylic acid... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1654443